

# DOUBLE TROUBLES – PRESENTING A SERIES OF DUAL PRIMARY MALIGNANCIES.

Dr SANTHOSH N

MCh Resident

Dept of Surgical Oncology

DPU, Pune.

Under Guidance of

Dr SAMIR GUPTA (Prof and Head)

DR PRASANT CHANDRA






Dept of Surgical Oncology

DPU, Pune.

# CASE1

- 46 year old female -Right breast lump since 5 months with history of easy fatiguability and backache.
- Examination of Right breast lump -upper outer quadrant lump 6x5 cm with single palpable axillary node -**cT<sub>3</sub>N<sub>1</sub>** lesion.
- Trucut biopsy breast lump- Invasive ductal carcinoma, NOS, triple negative breast cancer(TNBC), grade 3.
- Urinary Bence Jones proteins – positive

- PET- CT suggestive of Right breast lesion was 6x 5 cm with right axillary lymph node 2 x 2cm with diffuse FDG uptake involving axial and appendicular skeleton noted.
- Bone marrow biopsy -80% plasma cells with M band, 9.2 g/dL IgG Kappa, Serum B2 microglobulin – 10.6 mg/L.
- Multiple myeloma (MM)- stage RISS/ISS III
- Started on bortezomib + lenalidomide + dexamethasone -8 cycles.
- NACT 4 cycles – Adriamycin + Cyclophosphamide -for carcinoma breast.




- PETCT- post NACT suggestive of right breast lump- 3.5 x 3.1cm (SUVm 42.2 -> 19.7) and right axillary Lymph node- 1.4 x 0.5cm (SUVm 2.4 -> 2.5).
- Decrease in size of breast lesion and metabolic activity of skeletal lesions were noted.
- Patient underwent right sided modified radical mastectomy(MRM)
- Post operatively – 4 cycles of adjuvant paclitaxel chemotherapy,
- Weekly bortezomib and dexamethasone for multiple myeloma and is on follow up with no recurrent disease.

# CASE2



- 53 year old female presented with polypoidal growth in the left nasal cavity.
- HPE of biopsy from polypoidal lesion is s/o undifferentiated carcinoma .
- Wide local excision WLE (left cheek+ ala+vestible) with nasolabial flap with modified neck dissection ( MND )Type II was done.







- HPE of excised specimen is suggestive of **invasive malignant melanoma pT4bN2a** , with margins negative, 2/32 nodes positive for tumor, perineural invasion present .IHC is positive for HMB 45.
- Adjuvant immunotherapy was advised but due to financial constraints patient deferred the treatment.
- There is doubtful benefit of adjuvant chemotherapy and radiotherapy and patient was kept under surveillance.



- PET CT scan done after 2 months of follow up was suggestive of FDG avid intraluminal nodular lesion in proximal part of stomach.
- UGI endoscopy revealed polypoid lesion with ulcerated mucosa in proximal stomach below GEJ.
- Biopsy stomach lesion- Adenomatous polyp with Grade II Adenocarcinoma.



- As performance status of patient was good, Proximal partial gastrectomy was done.
- HPE was suggestive of **adenocarcinoma microinvasive** – pT1a- moderately differentiated, invades muscularis mucosa, all margins free , no lymphovascular invasion, no perineural invasion, no lymphnodes positive for tumor.




- 
- No Adjuvant treatment was required for Ca stomach. Patient is in follow up with no recurrent disease.

# CASE 3

- 60 year old gentleman presented with abdominal pain, decreased appetite , weight loss, bleeding PR since 2 months.
- On examination- liver is enlarged with hard, irregular liver border. Per rectal examination revealed grade 2 prostate, hard in consistency.
- CECT abdomen and pelvis suggestive of Multiple liver metastasis with enlarged prostate.

- Serum prostate specific antigen (PSA) -100 ng/ml, carcino embryonic antigen (CEA)- 64 ng/ml.
- TRUS- Prostate Biopsy diagnosed with adenocarcinoma with gleasons score 4+5- CA prostate with neuroendocrine differentiation.
- PSMA PET scan suggestive of - PSMA ligand uptake in prostate, inguinal -pelvic abdominal nodes, liver, skeletal deposits



PSMA PET scan suggestive of -  
PSMA ligand uptake in  
prostate, inguinal -pelvic  
abdominal nodes, liver, skeletal  
deposits.




- Colonoscopy suggestive of 2 small sessile polyp in rectum
- Biopsy- Rectal polyp- s/o poorly differentiated adeno carcinoma .
- IHC Rectal biopsy- CDX2 positive.


- IHC of liver biopsy- CK 7 ,CK20,CDX2 Negative, PSA strongly positive, CEA positive in few cells, suggestive of metastasis from **prostatic adenocarcinoma**




**a**




**b**




**c**



**d**



- 
- Bilateral Orchiectomy was done and bicalutamide was started .
  - Patient did not follow up subsequently and died of liver disease.

# CASE 4


- A 55 year old female presented with abdominal distention since 6 months with no h/o respiratory distress.
- USG abdomen and pelvis is suggestive of **22x19cm** cystic mass lesion arising from right ovary with multiple septae ( pelvis till epigastrium).
- Serum (beta HCG)- 2.9 mIU/ml, serum (AFP)-2.8 ng/ml, CA-19.9-2.1 u/ml, **CA 125 -137.9 U/ml-**, CEA- 3.8 ng/ml.



- Chest X ray – homogenous opacity in left upper lobe of lung.
- HRCT chest suggestive of 8.6x7.7x6.6cm solid soft tissue density lesion in left upper lobe showing heterogenous enhancement.
- CECT abdomen/pelvis suggestive of large cystic lesion from right ovary (32.5x18x28.5cm) with few areas of solid mural nodules and internal septae from the pelvis.

- Total abdominal hysterectomy and bilateral salphingo-oophorectomy (TAH + BSO) was done for huge ovarian mass.
- HPE s/o borderline mucinous cyst papillary tumor of ovary, outer surface free of tumor, with no vascular or stromal invasion







- Lung mass trucut biopsy HPE- plasmacytoma or inflammatory myofibroblastic tumor. IHC- CD138- Positive in plasma cells. Serum Immunoglobulin (IgG4) -normal.
- On fiberoptic bronchoscopy left middle lobe revealed- walls friable and bleed on touch.




**a**



**b**




**c**



**d**



- 
- In view of borderline mucinous cyst papillary tumor from ovary, no adjuvant chemotherapy was indicated.
  - For plasmacytoma patient underwent radiotherapy and improvement was seen after radiotherapy. Patient is on follow up with no new complaints.

# Treatment and Outcome

Patient number	Cancer association	Treatment		Outcome
		First cancer	Second cancer	
1	Breast/ Multiple myeloma	Modified radical mastectomy	Chemotherapy	Alive After 1 year after surgery
2	Nasal melanoma / Adenocarcinoma of stomach	WLE (left cheek+ ala+vestible) + nasolabial flap with + MND Type II	Proximal partial gastrectomy	Alive after 2 year of surgery
3	Prostate ca/ Rectal adenocarcinoma	B/L orchidectomy + hormonal therapy	-	Died of liver disease
4	Ovarian ca / Plasmacytoma	TAH+ BSO	Radiotherapy	Alive after 1 year of surgery

# DISCUSSION

- Multiple primary malignant tumor(MPMT) - Two or more different primary malignant tumors that occur in patients at same time or at different time.
- The occurrence for second primary **0.734-11.7%**.
- The incidence at our institution - **1.03 %**.
- Warren and Gates -diagnostic criteria:
  - 1) Each tumor must be distinct from each other;
  - 2) Each tumor must present definite features of malignancy; and
  - 3) The possibility that the one is a metastasis of another must be ruled out .

## **Risk factors**


- Genetic susceptibility/ cancer syndromes predisposing to malignancy
- Intensive exposure to carcinogens including chemotherapy / radiotherapy used in the treatment of first primary case.
- Tumour specific characters.


- Weibo Y et al in china -radiation induced cancers account for 23% of repeat carcinomas.
- Ricceri et al found that multiple malignancies were on the rise post radiotherapy like connective tissue, thyroid, breast, bone.
- The incidence of second primary carcinoma of oral cavity associated with radiotherapy for nasopharyngeal carcinoma was upto 11% as shown by Song et al.

1. Weibo Y, Zihao Y, Guozhen X and Yimin H: Radiation Oncology. 4th Edition, Beijing: Chinese Union Medical University Press, Beijing, China, 2008; pp 1374.

2. Ricceri F, Fasanelli F, Giraudo MT, et al. Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer*. 2015;137:940-8. <https://doi.org/10.1002/ijc.29462>

3. Song M, Zhuang SM, Chen SW, Zhang Q, Yang AK, Wang LP and Guo ZM: Survival study and treatment strategy for second primary tumors in the oral cavity in patients with nasopharyngeal carcinoma after definitive radiation. *Head Neck* 2012;34: 1551-1555.

- 
- The choice of treatment should depend upon the location of tumor, curative surgical resection margins, chemotherapy and radiotherapy.
  - If surgery is required it can be done so in a majority of cases with low rate of morbidity and mortality for both the tumors.

- 
- The prognosis of these patients depends upon aggressive biology of the cancer and the stage presentation of each individual tumor and not merely the occurrence of two primary tumors.
  - With the various therapeutic strategies that we have nowadays, given the stage presentation of the each individual cancers, successful management of these double primary tumors is possible.



- At present there is no specific treatment protocol of MPMN and many of the treating surgeons and physicians rely on cases reported.

## **RECOMMENDATIONS –**

- Separate cancer registry for MPMN's / hereditary syndromes can be considered and followed up more frequently than the routine population.
- As there are variety of combinations of MPMN'S and treatment of both cancers with chemotherapy if needed can be challenging .

# Conclusion

- It is mandatory that patients of MPMT's come for regular followup with adequate clinical and radiological imaging.
- When there is a diagnostic dilemma regarding primary and metastatic tumors, expert pathologist opinion, genetic analysis and IHC on both the tumors can provide the answer.
- Forming a cancer registry for MPMN's can be considered as there are variety of combinations of MPMN's.



THANK YOU